Programmable Chimeric Antigen Receptor T Cell Circuits With DNA Computing for Precision Tumor Therapy.

Area of Science:

• Immunology
• Biotechnology
• Genetics

Background:

• Chimeric antigen receptor (CAR) T cells show promise in cancer therapy but lack precise control over T cell activation, impacting safety and efficacy.
• Current CAR T-cell therapies face limitations in targeting specificity and tumor ablation capabilities.

Purpose of the Study:

• To develop a novel DNA-logic CAR (DL-CAR) system for programmable tumor targeting and precise ablation.
• To engineer a CAR system capable of recognizing specific antigen combinations and controlling T cell activation through Boolean logic.

Main Methods:

• Engineered DL-CAR system using HaloTag for DNA conjugation, enabling aptamer assembly for antigen recognition.
• Utilized DNA logic computation (AND, OR, INHIBIT gates) to control CAR T-cell activation and cytolysis.
• Evaluated DL-CAR system efficacy and selectivity in mouse models of cancer.

Main Results:

• DL-CAR-T cells demonstrated programmable targeting of tumor cells with specific antigen combinations.
• Boolean logic gates (AND, OR, INHIBIT) precisely controlled T-cell activation and tumor cell lysis.
• DL-CAR system achieved high efficacy in tumor eradication in vivo with enhanced selectivity.

Conclusions:

• The DL-CAR system offers a new platform for programmable CAR T-cell circuits.
• This approach enhances precision in cancer therapy by enabling combinatorial antigen recognition and controlled T-cell activation.
• DL-CAR technology holds potential for developing next-generation precision cancer treatments.